232 related articles for article (PubMed ID: 19645131)
1. Molecular characteristics therapy in AML.
Radich GP
Clin Adv Hematol Oncol; 2009 Jun; 7(6):11-4. PubMed ID: 19645131
[No Abstract] [Full Text] [Related]
2. Clinical trials in adult AML.
Stock W
Clin Adv Hematol Oncol; 2009 Jun; 7(6):8-10. PubMed ID: 19645130
[No Abstract] [Full Text] [Related]
3. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
4. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
[No Abstract] [Full Text] [Related]
5. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
6. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute myeloid leukemia in older patients.
Roboz GJ
Expert Rev Anticancer Ther; 2007 Mar; 7(3):285-95. PubMed ID: 17338649
[TBL] [Abstract][Full Text] [Related]
8. Strategies in the treatment of acute myeloid leukemia.
Lowenberg B
Haematologica; 2004 Sep; 89(9):1029-32. PubMed ID: 15377460
[No Abstract] [Full Text] [Related]
9. Genetics in the management of adult de novo AML.
Bloomfield CD
Clin Adv Hematol Oncol; 2003 Nov; 1(11):640, 645-6. PubMed ID: 16258460
[No Abstract] [Full Text] [Related]
10. Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.
Venugopal P; Manson S; Preisler HD
Cancer Treat Res; 2001; 108():257-65. PubMed ID: 11702603
[No Abstract] [Full Text] [Related]
11. Intensified induction therapy for children with AML.
Woods WG
Ann Hematol; 2004; 83 Suppl 1():S119-20. PubMed ID: 15124701
[No Abstract] [Full Text] [Related]
12. T-cell lymphomas.
Horwitz SM
Clin Adv Hematol Oncol; 2009 Jun; 7(6):380-2. PubMed ID: 19606072
[No Abstract] [Full Text] [Related]
13. Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.
Biggio V; Renneville A; Nibourel O; Philippe N; Terriou L; Roumier C; Amouyel P; Cottel D; Castaigne S; Dombret H; Thomas X; Fenaux P; Preudhomme C;
Leukemia; 2008 Mar; 22(3):655-7. PubMed ID: 17851556
[No Abstract] [Full Text] [Related]
14. Independent prognostic factors for AML outcome.
Grimwade D; Hills RK
Hematology Am Soc Hematol Educ Program; 2009; ():385-95. PubMed ID: 20008224
[TBL] [Abstract][Full Text] [Related]
15. Third biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
[No Abstract] [Full Text] [Related]
16. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Tobinai K
Semin Hematol; 2010 Apr; 47 Suppl 1():S5-7. PubMed ID: 20359583
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia: 2014 update on risk-stratification and management.
Estey EH
Am J Hematol; 2014 Nov; 89(11):1063-81. PubMed ID: 25318680
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
